Why the Noxopharm (ASX:NOX) share price is jumping 14% higher today

The Noxopharm Ltd (ASX: NOX) share price is going berserk today. We take a look at what the company released in its latest shareholder update.

While the S&P/ASX 200 Index (ASX: XJO) is slipping today, the Australian clinical-stage drug developer Noxopharm Ltd (ASX: NOX) is bucking the trend with its shares rising.

At the time of writing, the Noxopharm share price is up 14.13% to 52 cents.

A medical researcher works on a bichip, indicating share price movement in ASX tech companies

Image Source: Getty Images

Why is the Noxopharm share price increasing?

Cancer drug update

Noxopharm released a shareholder update to the market this morning pertaining to its drugs in development.

In the update, Noxopharm states that its immunotherapy drug, Veyonda, is emerging as a major new treatment. The company goes on to describe the potential value as 'multi-billion dollar', based on its ability to boost the effectiveness of all 3 current methods of cancer treatment: immune-oncology therapy, radiotherapy, and chemotherapy.

The immunotherapy drug is currently undergoing various testing by IONIC, LuPIN, and DARRT-2 to assess its ability in different applications.

Noxopharm has also advised that its NOXCOVID trial is progressing as planned. The aim of this drug is to block the cytokine release syndrome in COVID-19 patients, preventing deaths and long-term disability. The company foresees the trial to likely expand as COVID-related deaths rise across Europe.

Positioning for commercial transactions

Noxopharm later mentioned that it believes its leading position in restoring immune function to tumours will translate shortly into commercial discussions. Due to this, the company is building an in-house business development capability to meet this opportunity.

Future plans

Noxopharm detailed 2 programs it is focusing on for its drug pipeline for 2021. The first being treatments for pancreatic carcinoma and cholangiocarcinoma. The second being treatments for brain cancers, based on the inhibition of metabotropic glutamate receptor activity.

The company is expected to have identified lead drug candidates and be underway with standard pre-clinical testing programs by mid-2021.  

Lastly, Noxopharm has elaborated on the new subsidiary, Pharmorage Pty Ltd. The purpose of the new entity is to build upon an existing drug that was found to be potentially useful in treating cytokine release syndrome and septic shock. Pharmorage has reportedly initiated a number of drug discovery programs which will be reported on progressively throughout the year.

The Noxopharm share price has gained 102% over the last 12 months.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »

Army man holding a drone while the army woman holds the remote control.
52-Week Lows

Can DroneShield shares rebound from fresh 52-week low, or is there more downside ahead?

Investors have fallen out of love with the counter-drone operator’s shares.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Frustrated man looking exhausted while sitting at his desk with his laptop and carrying his glasses in his hand.
ASX Share Market News

5 things to watch on the ASX 200 on Tuesday

It looks set to be a tough session for Aussie investors.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

rubbish bins
Opinions

I've always loved Wesfarmers shares. But after a trip to Kmart, I'm not so sure

A weekend trip took some gloss off this stock.

Read more »